Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports

Схожие документы

• Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
  по: Diego Bagnasco, и др.
  Опубликовано: (2017-08-01)
• Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
  по: Diego Bagnasco, и др.
  Опубликовано: (2020-08-01)
• Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports
  по: Laura Pini, и др.
  Опубликовано: (2021-10-01)
• Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
  по: Rosalia Emma, и др.
  Опубликовано: (2018-10-01)
• COVID-19, Eosinophils, and Biologicals for Severe Asthma
  по: Carlo Lombardi, и др.
  Опубликовано: (2022-04-01)